Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Marinus Pharmaceuticals Inc    MRNS

MARINUS PHARMACEUTICALS INC (MRNS)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/17/2018 10/18/2018 10/19/2018 10/22/2018 10/23/2018 Date
6.14(c) 5.9(c) 5.72(c) 5.74(c) 5.67 Last
776 206 762 637 463 250 614 952 230 355 Volume
-5.10% -3.91% -3.05% +0.35% -1.22% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -34,5 M
Net income 2018 -33,0 M
Finance 2018 52,0 M
Yield 2018 -
Sales 2019 -
EBIT 2019 -52,2 M
Net income 2019 -49,4 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 0
Capitalization 233 M
More Financials
Company
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics.Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous,... 
Sector
Pharmaceuticals
Calendar
03/03 | 06:00amEarnings Release
More about the company
Surperformance© ratings of Marinus Pharmaceuticals In
Trading Rating : Investor Rating : -
More Ratings
Latest news on MARINUS PHARMACEUTICALS IN
10/11MARINUS PHARMACEUTICALS : Names Dr. Rolando Guterrez-Esteinou as VP of Clinical ..
AQ
10/10Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinica..
GL
10/09Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule..
GL
10/06MARINUS PHARMACEUTICALS : Announces Inducement Grants Under NASDAQ Listing Rule ..
AQ
10/05Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule..
GL
09/28MARINUS PHARMACEUTICALS : Completes Enrollment in its Magnolia Postpartum Depres..
AQ
09/26MARINUS PHARMACEUTICALS : Completes Enrollment in its Magnolia Postpartum Depres..
AQ
09/25Marinus Completes Enrollment in its Magnolia Postpartum Depression Study
GL
09/25MARINUS PHARMACEUTICALS : Announces Inducement Grants under NASDAQ Listing Rule ..
AQ
09/21MARINUS PHARMACEUTICALS : Announces Inducement Grants Under NASDAQ Listing Rule ..
AQ
More news
Sector news : Pharmaceuticals - NEC
04:17pAstraZeneca Adds Cancer Drugs to Pipeline with Innate Pharma Deal
DJ
03:33pPFIZER : Bain Capital Create Company to Develop Drugs for CNS Disorders -- Updat..
DJ
03:13pPFIZER : Bain Capital Create New CNS Company
DJ
02:44pCSL : Seqirus Gets FDA Approval for Afluria Quadrivalent in Young Children
DJ
01:29pBIOGEN : 3Q Profit Rises 18%; Beats Expectations
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
10/21-$0.14 EPS Expected for Marinus Pharmaceuticals Inc $MRNS This Quarter  
10/20Marinus Pharmaceuticals $MRNS Upgraded to Buy by ValuEngine  
10/19By the way, $MRNS spokesperson confirmed to me what you said previously about..
2
10/19Marinus Pharmaceuticals $MRNS Trading Down 5.1%  
10/18Want automatic email alerts for $OUTR $MNK $NAVI $MRNS $DARE? Subscribe to Ma.. 
More tweets
Qtime:25
News from SeekingAlpha
09/27Marinus Looks Like More Than A Me-Too 
08/02PREMARKET LOSERS AS OF 9 : 05 am (8/2/2018) 
08/02Marinus Pharmaceuticals misses by $0.08 
07/15WEEK 29 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
07/08WEEK 28 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
Chart MARINUS PHARMACEUTICALS INC
Duration : Period :
Marinus Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MARINUS PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 17,5 $
Spread / Average Target 205%
EPS Revisions
Managers
NameTitle
Christopher Michael Cashman Chairman, President & Chief Executive Officer
Edward F. Smith Chief Financial Officer, Secretary, Treasurer & VP
Jaakko Lappalainen Vice President-Clinical Development
Lorianne K. Masuoka Chief Medical Officer
Nicole Vitullo Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MARINUS PHARMACEUTICALS INC-29.66%239
JOHNSON & JOHNSON-0.48%374 244
PFIZER22.86%257 933
NOVARTIS5.63%220 104
ROCHE HOLDING LTD.-0.63%206 610
MERCK AND COMPANY28.97%192 044